History & Overview Annual Report President's Pages Center News Community Affairs

Make a Gift Cycle for Survival Fred's Team Rock & Run on the River Yankees Universe Fund Thomas Blake Sr. Memorial Research Fund Donating Blood & Platelets Volunteering Thrift Shop Park Avenue Potluck CELEBRATIONS

Press Releases In the News Information for Journalists News@MSKCC

Manhattan New Jersey Long Island Westchester

Working at Memorial Sloan-Kettering Work Sites College Recruitment About Nursing Job Fairs & Career Days IS Careers Job Search & Apply Online

Human Oncology and Pathogenesis Program

Timothy A. Chan

Ingo K. Mellinghoff

Charles L. Sawyers

Members of the Laboratory

Publications

King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL and Sawyers CL. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nature Genetics, in press.

Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen C, Higano CS, Beer TM, Hung DT, Scher HI, Jung M and Sawyers CL. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science 2009, published online April 9 2009; 10.1126/science.1168175 (Science Express Reports)

Welsbie D*, Xu J*, Chen Y*, Borsu L, Scher HI, Rosen N, Sawyers CL. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Research 2009, Feb 1;69(3):958-66. *equal contribution.

Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008 Dec 9;14 (6):485-93.

Sawyers CL. The cancer biomarker problem. Nature. 2008 Apr 3;452(7187):548-52.

Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008 Jan 22;5(1):e8.

Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007 Sep;117(9):2562-9.

Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL. (2007) Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN. Cancer Cell. 2007 Jun;11(6):555-69.

Talpaz M, Shah N, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise L, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen T, Huang F, Decillis A, Sawyers CL. Activity of the ABL kinase inhibitor desatinib in imatinib-resistant Philadelphia chromosome positive leukemias. New Engl J Med 2006; 324:2531-2541.

Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006: 12: 122-127.

Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267-1270.

Site Map \| Index	Legal Disclaimer \| Privacy Practices \| Public Notices

©2009 Memorial Sloan-Kettering Cancer Center. 212-639-2000 1275 York Avenue New York, NY 10065.	PublicAffairs@mskcc.org